Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 204-589-7 | CAS number: 122-99-6
Toxicity to other aquatic organisms
Administrative data
Link to relevant study record(s)
Description of key information
Additional information
Ovaries of adultX.laeviswere excised (stage V and VI) and exposed to different test concentrations of 2-phenoxyethanol in glass plates at 4°C for 24 hours in presence and absence of either progesterone or androstenedione. Germinal vesicle breakdown, as a marker of the final stage of amphibian oocyte maturation (oogenesis), was determined visually and was verified by cracking the fixed oocytes. Two independent triplicate measurements were conducted. The potency was expressed as IC25 at which 25% of progesterone or androstenedione-induced GVBD occurred and was determined to be 1.9 and 5.3 µg/L for 2-phenoxyethanol, respectively.
Further, the binding capacity of 2-phenoxyethanol to oocyte plasma membrane receptor and to androgen was investigated by adding [3H]progesterone and [3H]androstenedione to the exposed oocytes. Oocytes or oocyte plasma membrane proteins were exposed (microinjected) with 2-phenoxyethanol equivalent to the IC25 and added radiolabeled hormones were separated from the oocytes or plasma by filtration or centrifugation. The OMPR and AR binding capacity of 2-phenoxyethanol was determined to be 10.8% relative to progesterone and 25.1% relative to androstenedione, respectively.
It was not investigated whether the effect concentrations are cytotoxic to the oocytes and 2-phenoxyethanol acted via both pathways (oocyte plasma membrane receptorand and androgen). This bimodal inhibition was unexpected and raised questions about the specificity of the assay with regard to the biological relevance.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
